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Abstract
Background: Metformin, a biguanide, is one of the most commonly prescribed treatments for type 2 diabetes and
has recently been recommended as a potential drug candidate for advanced cancer therapy. Although Metformin
has antiproliferative and proapoptotic effects on breast cancer, the heterogenous nature of this disease affects the
response to metformin leading to the activation of pro-invasive signalling pathways that are mediated by the focal
adhesion kinase PYK2 in pure HER2 phenotype breast cancer.
Methods: The effect of metformin on different breast cancer cell lines, representing the molecular heterogenicity of
the disease was investigated using in vitro proliferation and apoptosis assays. The activation of PYK2 by metformin
in pure HER2 phenotype (HER2+/ER−/PR-) cell lines was investigated by microarrays, quantitative real time PCR and
immunoblotting. Cell migration and invasion PYK2-mediated and in response to metformin were determined by
wound healing and invasion assays using HER2+/ER−/PR- PYK2 knockdown cell lines. Proteomic analyses were used
to determine the role of PYK2 in HER2+/ER−/PR- proliferative, migratory and invasive cellular pathways and in
response to metformin. The association between PYK2 expression and HER2+/ER−/PR- patients’ cancer-specific
survival was investigated using bioinformatic analysis of PYK2 expression from patient gene expression profiles
generated by the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) study. The effect of
PYK2 and metformin on tumour initiation and invasion of HER2+/ER−/PR- breast cancer stem-like cells was
performed using the in vitro stem cell proliferation and invasion assays.
Results: Our study showed for the first time that pure HER2 breast cancer cells are more resistant to metformin
treatment when compared with the other breast cancer phenotypes. This drug resistance was associated with the
activation of PTK2B/PYK2, a well-known mediator of signalling pathways involved in cell proliferation, migration and
invasion. The role of PYK2 in promoting invasion of metformin resistant HER2 breast cancer cells was confirmed
through investigating the effect of PYK2 knockdown and metformin on cell invasion and by proteomic analysis of
associated cellular pathways. We also reveal a correlation between high level of expression of PYK2 and reduced
survival in pure HER2 breast cancer patients. Moreover, we also report a role of PYK2 in tumour initiation and
invasion-mediated by pure HER2 breast cancer stem-like cells. This was further confirmed by demonstrating a
correlation between reduced survival in pure HER2 breast cancer patients and expression of PYK2 and the stem cell
marker CD44.
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Conclusions: We provide evidence of a PYK2-driven pro-invasive potential of metformin in pure HER2 cancer
therapy and propose that metformin-based therapy should consider the molecular heterogeneity of breast cancer
to prevent complications associated with cancer chemoresistance, invasion and recurrence in treated patients.
Keywords: Pure HER2 breast Cancer, Metformin, PYK2/PTK2B, Chemoresistance, Breast cancer stem cells
Backgound
Cancer cells are constantly developing cellular mecha-
nisms that confer resistance to chemotherapeutic com-
pounds, and this leads to cancer recurrence and decreased
survival in cancer patients [1, 2]. This therapeutic limita-
tion is also observed in advanced breast cancer, where
cancer cells escape the cytotoxic effects of chemotherapies
by developing multiple drug resistance [3]. Metformin, a
drug that is used for the treatment of type 2 diabetes, has
been proposed as an alternative therapy of advanced
breast cancer [4–7]. The interest in metformin as
therapeutic compound, is based on meta-analyses that in-
dicated that patients with type 2 diabetes have a reduced
incidence of pancreatic, colorectal and breast cancers. An
improvement in survival was also reported in metformin-
treated type 2 Diabetes patients with colorectal, lung and
liver cancers [8–11]. Although, in vitro studies of metfor-
min effect on breast cancer cell lines confirmed the anti--
proliferative potential of this drug [6, 12, 13], it is not
yet clear whether the molecular heterogeneity of this
disease interferes with the response to metformin
treatment [14, 15].
The protein tyrosine kinase PYK2, also known as
PTK2B, is a non-receptor tyrosine kinase involved in the
regulation of cell growth, proliferation, survival, migra-
tion and invasion [16–18]. As a member of FAK (Focal
Adhesion Kinase) family of kinases, PYK2 functions as a
linker between transmembrane glycoproteins and actin
cytoskeleton [19]. In cancer, PYK2 plays an important
role in tumourigenesis, invasion and metastasis and its
high level of expression in patients’ tumours correlates
with poor outcomes [20–27]. In breast cancer, PYK2 ex-
pression is increased in early and advanced ductal breast
cancer and correlates with an increased expression of
HER2 [28]. Although this involvement could be ex-
plained by the role of PYK2 in breast cancer migration
and invasion [24], its role in breast cancer chemoresis-
tance and potentially in associated breast cancer recur-
rence is unknown.
In this study, we demonstrate that breast cancer cells
characterised by the HER2 phenotype (HER2+/ER−/PR-)
are more resistant to metformin treatment. We
demonstrate that unlike cells that are luminal A, luminal
B, claudin low or basal-like, HER2+/ER−/PR- (HER2)
cells exhibit increased cell proliferation and decreased
apoptosis, in response to metformin. More importantly,
we report that metformin treatment leads to an increase
in PYK2 expression that is associated with cell invasion
of HER2+/ER−/PR- cells. These results were confirmed
by proteomic analysis which indicated that several path-
ways involved in cancer invasion were affected follow-
ing PYK2 knockdown. Furthermore, analysis of PYK2
expression from HER2+/ER−/PR- breast cancer pa-
tients indicates a correlation between high expression
levels of PYK2 and patients’ reduced survival. Finally,
we show a role of PYK2 in cancer initiation and in
regulating self-renewal and invasion of HER2+/ER
−/PR- cancer stem-like cells and in response to met-
formin. Overall, this study suggests that future appli-
cations of metformin in breast cancer therapy should
consider the molecular heterogeneity of this disease,
and particularly the HER2 breast cancer phenotype,
to prevent the development of a more aggressive form
of breast cancer, associated with metformin-based
therapy.
Methods
Cell lines, growth conditions and metformin treatment
The human breast cancer cell lines BT-474, MCF-7,
MDA-MB-231 and MDA-MB-468 and SkBr-3 were pur-
chased from ATCC (ATCC-HTB-20, ATCC-HTB-22,
ATCC-HTB-26, ATCC-HTB-132 and ATCC-HTB-30).
The breast cancer cell line MDA-MB-453 was purchased
from Deutsche Sammlung von Mikroorganismen und
Zellkulturen (DSMZ) (ACC65). All cell lines were cul-
tured in their dedicated media. The cell lines were used,
for the experiments, at a very low passage and were
regularly morphologically checked. BT-474 cell line was
cultured in Hybri-Care media. Minimum Essential
Medium Eagles (EMEM) from SLS (Lonza) was used to
culture the MCF-7 cell line with addition of 0.01 mg/ml
insulin solution (SIGMA). LEIBOVITZ (L-15) media
complemented with 1% L-Glutamine (SLS (Lonza)) was
used for both MDA-MB-231, MDA-MB-468 and
MDA-MB-453. While, Mc Coy’s 5A was used for cultur-
ing the SkBr-3 cell line. 10% fetal bovine serum (FBS)
was added to all types of media as supplementary agent
in accordance with ATCC recommendations. BT-474,
MCF-7, and SKBR-3 were incubated at 37 °C with 5%
CO2, while MDA-MB-231 and MDA-MB-468 are
incubated at 37 °C, in humidified atmosphere without
CO2. Metformin (1, 1-Dimethylbiguanide hydrochloride
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97%, D150959-5G, Sigma-Aldrich, UK) was dissolved in
culture media at concentrations of 1M and 10-2M was
used as a stock to prepare different concentrations for
treatment of cells (1, 2, 5, 10, 15, 20, 25) mM and (0.01,
0.05, 0.1, 0.5) mM consecutively.
Generation of PYK2 knockdown cell lines
Lentiviral PTK2B shRNA plasmids were purchased
from Sigma-Aldrich (MISSION shRNA Plasmid DNA
protein tyrosine kinase 2 beta (PTK2B/PYK2)
SHCLND-NM_004103. 3-763S1C1 & NM_004103.
3-4018S21C1). The lentiviral packaging mix was also
purchased from Sigma (SHP001). Plasmids were
transfected using Lipofectamine™ 3000 Reagent
(L3000001, ThermoFisher Scientific) and following
manufacturer recommendations. The lentiviral parti-
cles used to infect SkBr3 and MDA-MB-453 were
produced corresponding to the manufacturer recom-
mendations and as previously described [29].
Cell proliferation assay
Cell proliferation described in Fig. 1 was measured using
The CyQUANT® NF assay (Molecular Probes™ C35007)
and following manufacturer recommendations.
Fluorescence intensity was measured using a fluores-
cence microplate reader TECAN ULTRA fluorescence
spectrophotometer with excitation at ~ 485 nm and
emission detection at ~ 530 nm (Infinite® 200 PRO).
Cell proliferation described in Fig. 3 was performed
using the xCELLigence system, and cell index was
measured following manufacturer recommendations.
The results were analysed using RTCA software
(Real-time cell analysis software Xcelligence).
Cell apoptosis assay
Cells were plated in 6-well plates at a density of 1 × 105
cells/well in 2 ml of media and incubated for 24 h. The
media was removed, and the cells were treated with
different concentrations of metformin (0-25 mM) and
incubated for 24 h and 48 h, respectively. The cells were
collected after 24 and 48 h of treatment, and the number
of cells were counted by the Chemometec Nucleo
Counter® NC-250 TM (Chemometec). The tubes were
incubated in the dark for 15 min and 350 μL of Annaxin
V Binding Buffer and 10 μL of 1/20 of Propidium Iodide
solution (PI) were added. The proportion of living cells,
early apoptotic cells, and necrotic cells were determined
using a flow cytometer (Beckmen Coulter Gallios Flow
Cytometer).
Immunoblotting
Immunoblotting was performed as previously described
[30]. In brief, metformin-treated and untreated breast
cancer cells were collected, washed with 1X PBS, lysed
in 1X solution containing 50mM Tris-HCl (pH 6.8),
100 mM dithiothreitol, 2% (w/v) SDS, 0.1% (w/v) bro-
mophenol blue and 10% (v/v) glycerol, and loaded on
Tris/glycine SDS-polyacrylamide gels. The proteins on
gels were transferred onto Amersham Hybond-P
PVDF membranes (GE Healthcare, Life science,
Chalfont, UK). Membranes were blocked with 10%
(w/v) Marvel milk/tris-buffered saline (TBS) solution
with 0.01% (v/v) Tween-20 (TBST), washes in TBST
and incubated with primary antibodies (PYK2 Anti-
body (9H12L1), 1: 500 for IB, 700183, Invitrogen,
Thermo Fisher Scientific; anti-b-actin, 1:5000 for IB,
A5441, Sigma-Aldrich, St Louis, MO, USA) (in block-
ing solution) overnight at 4 °C, and followed by wash-
ing and incubation with secondary antibodies for 1 h
at room temperature, prior to visualisation using
Rapid Step ECL reagent (Calbiochem, Billerica, MA,
USA) and a CCD camera -Western blot imager
(Syngene).
Gene expression and microarrays analyses
Microarrays analysis were performed from RNAs
extracted from cells using STAT 60 and RNeasy Mini
Kit (50) from QIAGEN and following the manufac-
turer’s instructions protocol. 200 ng of total RNA was
labelled using Agilent low input QuickAmp one-color
labelling kit. Quality of labelling checked using nano-
drop 8000 and hybridised onto an Agilent Human GE
4x44K v2 microarrays at 65 °C for 16 h. Slides were
washed and scanned using a GenePix pro- 4100A
scanner, quality controls and raw data of the scanned
images were generated using Agilent feature extrac-
tion software V11.0. Raw data was normalised using
Partek Genomic Suit V 6.0 and used for ANN ana-
lysis. Microarrays gene expression data were used for
pathways analysis using Panther Pathway. Gene
expression of IRF-9, PTK2B, C2ORF42 and DHFR2
were assessed by Real-time quantitative PCR using
the following primers: FH1_IRF9:5′-CTCAGAAA
GTACCATCAAAGC-3′; RH1_IRF9:5′- TCATTATTG
AGGGAGTCCTG-3′; FH1_PYK2: 5′-AATGCACTT-
GACAAGAAGTC-3′; RH1_PYK2:5′-GCTTTAAGTTC
TCCTGCATC-3′; FH1_C2orf42: 5′-AGCTTTTGTT
CGGAAAGATG-3′; RH1_C2orf42: 5′-GCATCTCTG
GGGTATCTAAG-3′; FH1_DHFR2:5′-CGCTGTGTCC
CAAAACATGG-3′; RH1_DHFR2: 5′- GAATTCATTC
CTGAGCGGCG-3′. The gene expression microarrays
data was deposited in the online database ArrayEx-
press under the accession number: E-MTAB-7737.
Mass spectrometry analysis
Cell lysates (100 μg) were reduced/alkylated and
digested as described previously. Next, samples were
de-salted and concentrated using HyperSep C18 spin
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tips (10-200 μL size) (Thermo Scientific) using the
manufacturer recommended protocol. Samples were
dried and resuspended in 5% acetonitrile + 0.1% for-
mic acid for MS analysis in both SWATH and IDA
(information dependent acquisition) modes.
Mass spectrometry
Each sample was analysed on a SCIEX TripleTof 6600
mass spectrometer coupled in line with an Eksigent
ekspert nano LC 425 system running in microflow as
described previously [31] with minor modifications. In
Fig. 1 Effect of metformin on cell proliferation and apoptosis of breast cancer cell lines representing different phenotypes of breast cancer.
a, b Effect of different concentrations of metformin on cell proliferation of BT-474, MCF-7, MDA-MB-231, MDA-MB-468 and SkBr3, 24 h and 48 h
post-treatment. N = 3 (6 replicates). c, d Effect of different concentrations of metformin on apoptosis of BT-474, MCF-7, MDA-MB-231, MDA-MB-
468 and SkBr3, 24 h and 48 h post-treatment. N = 3 (2 replicates). The statistical values are provided as Additional file 4: Data S1. e Heatmap of
microarray analysis showing upregulated (in red) and downregulated genes (in blue) in untreated vs. treated cells. Bonferroni corrected P value
≤0.05. N = 6 (6 replicates). f RT-PCR analysis of relative gene expression of selected IRF-9 and PYK2 (Upregulated), and c2orf42 and DHFR2
(downregulated). N = 3 (3 replicates). g, h Immunoblot images representing PYK2 expression in metformin treated and untreated SkBr3 and
MDA-MB-453 cell lines. Densitometric ratio is measured by Arbitrary Units (AU). Student t-test, **P = 0.0030 and ***P = 0.0006. N = 3 (3 replicates)
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brief, 6 μg (3 uL) of sample was injected via trap/elute.
The following linear gradients were used (5 uL/min):
mobile phase B (acetonitrile + 0.1% formic acid) over
mobile phase A (0.1% formic acid) as follows: SWATH
(57min run) increasing from 3 to 30% over 38 min, 30
to 40% over 5 min, 40 to 80% over 2min; IDA (87 min
run) increasing from 3 to 30% over 68 min, 30 to 40%
over 5 min, 40 to 80% over 2 min followed by wash and
re-equilibration.
Library generation, spectral alignment and fold change
analysis
IDA mass spectrometry files were searched using
ProteinPilot software 5.0.1 (SCIEX) with the following
search criteria: exclude biological modifications,
thorough ID, searching the UniProt Swiss-Prot human
database (March 2018 release). The resulting ion library
file was aligned using endogenous peptides to the
SWATH files and processed using the OneOmics cloud
processing platform (SCIEX, Warrington UK) as
described previously [32].
Sphere formation assay
Metformin-treated and untreated SKBR-3 cells were har-
vested and counted and then cultured in complete
Mammocult™ medium (Stem Cell Technologies) in
ultra-low attachment plates (Corning) at a density of 2 ×
104 viable cells/mL. The number of spheres that
developed in each condition was counted after 10 days
culture in a 5% CO2, humidified incubator at 37 °C.
Flow cytometry
Analysis of CD44+/CD24−/low breast CSC surface markers
expression
The spheres were collected by gentle centrifugation and
dissociated using trypsin-EDTA. The resulting single
cells were then washed in PBS prior to the addition of
fluorochrome-conjugated monoclonal antibodies against
human CD44 (APC; clone IM7) and CD24 (PE; clone
ML5) (Biolegend) for 30 min at 4 °C in the dark. The
LIVE/DEAD™ Fixable Violet Dead stain (Invitrogen) was
used for dead cells exclusion. The labelled cells were
then washed in PBS, re-suspended in Coulter Isoton™ di-
luent and analysed on a Gallios™ flow cytometer using
Kaluza™ v1.3 acquisition and analysis software (Beckman
Coulter).
AldeRed ALDH detection assay
The AldeRed™ Detection Assay (SCR150, Merck Millipore)
was used in accordance with the manufacturer’s
instructions. Briefly, 2 × 105 cells were incubated with
the AldeRed 588-A substrate for 40 min at 37 °C,
baseline fluorescence was established using negative
control samples incubated with the ALDH1 inhibitor,
diethylaminobenzaldehyde (DEAB). Subsequently, cells
were centrifuged, re-suspended in AldeRed assay
buffer and analysed on a Gallios™ flow cytometer
using Kaluza™ v1.3 acquisition and analysis software
(Beckman Coulter).
Cell migration and invasion assays
A wound-healing assay (Scratch assay) was applied to
different breast cancer PYK2 knockdown cell lines
following this protocol. Briefly, the cells were counted to
1 × 106 cells and seeded in 6 well plates with 2 mL of cell
dedicated media supplemented with Puromycin (3 μg/
mL) as non-treated cells and supplemented with
Puromycin and Metformin (1 μL/mL) as treated cells.
The following day the media was removed and instead
serum-free media was added (to prevent cell prolifera-
tion). After 24 h, the media was removed, and the cells
were washed with 1 mL of DPBS for each well. Scratches
were performed vertically by using a 200 μL pipette tip.
The cells were washed twice with 0.5 mL (DPBS) and
fresh serum-free media was added to each well (with or
without metformin). The measurements were carried
out at time 0 and 48 h by utilising the LCM and Axiovi-
sion software for imaging the scratches. The invasion
assay has been implemented according to Cultrex® BME
Cell Invasion Assay 96 well kit (R&D Systems) manufac-
turer protocol. This assay has been performed using un-
treated and metformin-treated MDA-MB-453 and SkBr3
control and PYK2 knockdown cell lines following the
manufacturer’s recommendations. For the stem cell
invasion assay, untreated and treated spheres were disso-
ciated to obtain single cells for the invasion assay. The
cells in the bottom chamber were labelled by Calcein
AM and the quantification of the number of cells was
performed using the plate reader Infinite M200 Pro
TECAN at 585 nm excitation and 520 nm emission.
Statistical analysis
The analysis was performed using patient gene expres-
sion profiles generated by the Molecular Taxonomy of
Breast Cancer International Consortium (METABRIC)
study [33] using Illumina HT-12 v3.0 Gene Expression
BeadChip. For the here conducted study, patients were
selected with a recorded overall survival (OS) (censored
or complete) of ≤5 years. This resulted in a total number
of 610 patients. Of these 610 patients, 84 were a pure
HER2+ population. Kaplan-Meier analysis was per-
formed on a median separation of the population by
gene expression, resulting in equal patient numbers per
group. Median survival time is shown in years for each
group. Correlation analysis was performed using Pearson
correlation. A p-value below 0.05 was considered signifi-
cant. The probe ID used for the PTK2B (PYK2) analysis
was ILMN_1732318.
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Results
HER2+/ER−/PR- breast cancer cells are resistant to
metformin treatment
To investigate the effect of metformin on the different
subtypes of breast cancer, we investigated its effect on
the proliferation and apoptosis of BT-474 (Luminal B),
MCF-7(Luminal A), MDA-MB-231(Claudin low),
MDA-MB-468 (Basal-like) and SkBr3 (HER2) cell lines.
The cells were treated with increasing concentrations
of metformin: 0.01, 0.05, 0.1, 0.5, 1, 2, 5, 10, 15, 20
and 25 mM, and a proliferation assay was performed
24 h and 48 h following treatment (Fig. 1 a and b). All
metformin-treated breast cancer cell lines showed a de-
creased proliferation 24 h and 48 h post-treatment, how-
ever, we observed that the proliferation of the HER2+/ER
−/PR- breast cancer cell line was the least affected by met-
formin 48 h post-treatment (Fig. 1b). Apoptosis experi-
ments that were performed and analysed by flow
cytometry using the apoptosis marker annexin V,
indicated that SkBr3 cells and although not biologically
significant, had less apoptotic cells 24 h and 48 h following
treatment, and when compared to MCF-7, MDA-MB-231
and MDA-MB-468 breast cancer cell lines (Fig. 1c and d).
Further apoptosis analysis using another HER2 breast
cancer cell line MDA-MB-453 resulted in similar results
to the ones obtained with SkBr3 (Additional file 1:
Figure S1A) These results demonstrate that the SkBr3
breast cancer cells, characterised by the HER2+/ER−/PR-
phenotype (HER2), are more resistant to metformin as
they were less affected by the apoptotic effect of metfor-
min and could maintain a higher proliferation ability
compared to the other breast cancer cell lines.
Metformin promotes the expression of PYK2 in HER2+/ER
−/PR- cells
The resistance of SkBr3 cells to metformin is likely to be
driven by the expression of genes and associated cellular
pathways. To investigate this, we performed microarrays
analysis of mRNAs from 48 h metformin-treated (1 mM
concentration) and untreated SkBR3 cells. Several genes
that were upregulated and downregulated in response to
metformin treatment were identified (Fig. 1e). The re-
sults of microarray analysis were confirmed by qRT-PCR
through investigating the levels of gene expression of
PYK2 (Protein Tyrosine Kinase 2 Beta) and IRF9 (Inter-
feron regulatory factor 9) that were found upregulated,
and C2ORF42 (Chromosome 2 Open Reading Frame 42)
and DHFR2 (dihydrofolate reductase 2) that were found
downregulated (Fig. 1f ). PYK2 role in tumourigenesis
and in breast cancer invasion is well known [24, 34], and
thus, we selected this molecule for further studies to
determine its role in HER2+/ER−/PR- breast cancer and
in response to metformin treatment. To confirm the in-
creased expression of PYK2 in HER2+/ER−/PR- breast
cancer cells following metformin treatment, immuno-
blotting experiments were performed with PYK2
antibody and using whole cell extracts from SkBr3 and
MDA-MB-453 breast cancer cell lines. The
MDA-MB-453 is another HER2+/ER−/PR- breast cancer
cell that was used for this study. The results confirmed
the increase of PYK2 expression at the protein level and
in response to metformin treatment (Fig. 1g and h). This
increase was also observed for the triple positive breast
cancer cell line BT-474 but was nor observed for the other
cell lines tested (Additional file 1: Figure S1 D and E).
PYK2 promotes migration and invasion of HER2+/ER−/PR-
breast cancer cells and in response to metformin
treatment
To investigate the potential role of PYK2 in migration
and invasion of HER2+/ER−/PR- breast cancer cells and
in response to metformin (1 mM), SkBr3 and
MDA-MB-453 PYK2 knockdown cell lines were gener-
ated (Fig. 2a and b, Additional file 1: Figure S1B and C).
Cell migration and invasion investigated using scratch
and cell-well invasion assays, demonstrated significant
decreases in these processes in metformin-untreated
PYK2 knockdown cells, and when compared to the con-
trol (pLKO.1 empty vector) (Fig. 2 c and d, and Fig. 3 a
and b). A decrease in cell migration and invasion was
also observed in metformin-treated PYK2 knockdown
cells, and when compared to the control (pLKO.1 empty
vector) (Fig. 2 c and d, Fig. 3 a and b, and
Additional file 2: Figure S2). These results indicate that
metformin-induced migration and invasion in SkBr3 and
MDA-MB-453 breast cancer cell lines may require
PYK2. On the contrary, PYK2 knockdown increased cell
proliferation of SkBr3 and MDA-MB-453 cells, sug-
gesting an antiproliferative function of PYK2 in HER2
+/ER−/PR- breast cancer cell lines (Fig. 3c and d,
Additional file 2: Figure S2). Although metformin
treatment did not affect the proliferation of SkBr3
PYK2 knockdown cells, a significant decrease was ob-
served in MDA-MB-453 PYK2 knockdown cells. Col-
lectively, these results demonstrate that PYK2 plays a
dual role in tumourigenesis and cancer progression
via promoting invasion and preventing proliferation of
HER2+/ER−/PR- breast cancer cells (Fig. 3e).
High level of PYK2 expression correlates with decreased
survival of HER2+/ER−/PR- breast cancer patients
Although a previous study has shown a correlation
between high level of expression of PYK2 and breast
cancer progression [34], the role of PYK2 in this process
and specifically in HER2+/ER−/PR- breast cancer is still
unclear. To examine this, the association of PYK2
expression with cancer-specific survival in a cohort of
patients with HER2+/ER−/PR- breast cancer was
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investigated by bioinformatics analysis of PYK2 expres-
sion using patient gene expression profiles generated by
the Molecular Taxonomy of Breast Cancer International
Consortium (METABRIC) study [33]. In this analysis,
the capacity of high or low expression of PYK2 to pre-
dict clinical outcome was assessed. A significant reduc-
tion in cancer-specific survival (χ2 = 6.109, P = 0.0134)
over a 5-year term was associated with high expression
of PYK2, and when compared to cancer-specific survival
in patients with low expression of PYK2 (Fig. 4a). This
result was further confirmed using Cox regression
analysis (Fig. 4b) Although analysis of the capacity of
high or low expression of PYK2 to predict
cancer-specific survival in the total cohort of patients
showed a non-statistically significant reduction associ-
ated with high expression of PYK2 (χ2 = 1.19, p = ns)
(Fig. 4c), the same analysis excluding HER2+/ER−/PR-
breast cancer patients resulted in no difference in
cancer-specific survival between low and high expression
of PYK2 (χ2 = 1.107, p = ns) (Fig. 4d).
Fig. 2 Effect of PYK2 knockdown on cell migration of the HER2+/ER−/PR- breast cancer cell lines SkBr3 and MDA-MB-453. a, b Immunoblot
images representing PYK2 expression SkBr3 and MDA-MB-453 control (pLKO.1 empty vector) and PYK2 knockdown cells. N = 3 (3 replicates). c
Wound healing assay (scratch assay) using SkBr3 control and PYK2 knockdown metformin treated and untreated cells, and the corresponding
data quantifying gap closure at time points 0 and 48 h following scratching. Anova ****P = < 0.0001, ***P = 0.0003 (Empty vector vs. PYK2
shRNA1), ***P = 0.0004 (Empty vector vs. PYK2 shRNA2). d Data quantifying gap closure at time points 0 and 48 h following scratching Wound
healing assay (scratch assay) using MDA-MB-453 control and PYK2 knockdown metformin treated and untreated cells. Anova ****P = < 0.0001.
N = 3 (2 replicates)
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Cellular pathways associated with PYK2 function in HER2
+/ER−/PR- cells and in response to metformin treatment
To further investigate the role of PYK2 in proliferation
and invasion of HER2+/ER−/PR- breast cancer cells, we
performed mass spectrometry analyses of protein
extracts from untreated control (pLKO.1 empty vector)
and untreated and treated PYK2 knockdown SkBr3 cells
(Fig. 4a and b). 3546 proteins were quantified by
SWATH-MS and processed using OneOmics. The
analyses identified several significantly differentially
expressed proteins that were common to both untreated
control (pLKO.1 empty vector) vs. untreated PYK2
knockdown and untreated control (pLKO.1) vs. treated
PYK2 knockdown (Fig. 5a, b, c d and Additional file 5:
Data S2). Downregulated proteins common to both
groups were associated with cellular pathways such as
Fig. 3 Effect of PYK2 knockdown on cell proliferation and invasion of the HER2+/ER−/PR- breast cancer cell lines SkBr3 and MDA-MB-453. a Cell
invasion assay using SkBr3 cells metformin treated and untreated and the corresponding data quantifying of number of invading cells (48 h with
or without treatment). Anova ****P = < 0.0001, **P = 0.0025 (Treated empty vector vs. treated PYK2 shRNA1), ***P = 0.0032 (Treated empty vector
vs. treated PYK2 shRNA2). N = 3 (2 replicates). b Cell invasion assay using MDA-MB-453 metformin treated and untreated cells, and the
corresponding data quantifying number of invading cells (48 h with or without treatment). Anova ****P = < 0.0001, **P = 0.0032 (Empty vector vs.
treated empty vector), **P = 0.0030 (Empty vector vs. PYK2 shRNA1), **P = 0.0017 (Empty vector vs. PYK2 shRNA1), ***P = 0.0005 (Treated empty
vector vs. treated PYK2 shRNA2), ***P = 0.0005 (Treated empty vector vs. treated PYK2 shRNA1). N = 3 (2 replicates). c Cell proliferation assay using
SkBr3 metformin treated and untreated cells, and the corresponding data quantified as cell index (48 h with or without treatment). Anova,
***P = 0.0001 (Empty vector vs. PYK2 shRNA1), ***P = 0.0004 (Empty vector vs. PYK2 shRNA2), ***P = 0.0002 (Treated empty vector vs. treated PYK2
shRNA1), **P = 0.0003 (Treated empty vector vs. treated PYK2 shRNA2). N = 3 (2 replicates). d Cell proliferation assay using MDA-MB-453
metformin treated and untreated cells, and the corresponding data quantified as cell index (48 h with or without treatment). Anova, **P = 0.0034
(Empty vector vs. treated empty vector), **P = 0.0010 (Empty vector vs. PYK2 shRNA1), ***P = 0.0003 (Empty vector vs. PYK2 shRNA2), **P = 0.0060
(Treated empty vector vs. treated PYK2 shRNA1), **P = 0.0022 (Treated empty vector vs. treated PYK2 shRNA1), ***P = 0.0007 (Untreated PYK2
shRNA1vs. treated PYK2 shRNA1), ***P = 0.0004 (Untreated PYK2 shRNA2vs. treated PYK2 shRNA2). N = 3 (2 replicates). e Schematic representation
of the dual role of PYK2 in proliferation, migration and invasion of HER2+/ER−/PR- breast cancer in response to metformin
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cell adhesion, migration, invasion, tumour suppression
and apoptosis (Fig. 5c), whereas, the upregulated pro-
teins were mostly associated with cell metabolism
(Fig. 5d). Proteins that were specifically found in un-
treated control vs. PYK2 knockdown, and that were
downregulated, are involved in cell adhesion, migra-
tion and invasion (Fig. 5e); while the upregulated
ones are involved in metabolism, transcription and
tRNA processing (Fig. 5f ). Proteins that were specific-
ally found in untreated control vs. treated PYK2
knockdown and that were downregulated, are mainly
involved in translation (downregulated expression)
(Fig. 5g), while the upregulated ones are involved in
metabolism and protein processing (upregulated
expression) (Fig. 5h). Several proteins that involved in
cell adhesion, migration, invasion, tumour suppression
and apoptosis are also found upregulated and
downregulated in MDA-MB-453 untreated control
(pLKO.1) vs. untreated or treated PYK2 knockdown
(Additional file 3: Figure S3 and Additional file 6:
Data S3). Although several pathways appear to be
involved in PYK2 function in HER2+/ER−/PR- breast
cancer cells, the above results confirm our observa-
tions of the role of PYK2 in cell migration and
invasion.
PYK2 promotes cell invasion of HER2+/ER−/PR- breast
cancer stem-like cells and in response to metformin
treatment
Cancer stem-like cells are associated with chemoresis-
tance and recurrence in patients following chemotherapy
[35]. PYK2 has been shown to promote breast cancer
stem cell enrichment in response to chemotherapy [36].
To investigate this possibility, sphere formation assays
(self-renewal) were performed using untreated and
treated control (pLKO.1 empty vector) and PYK2
knockdown SkBr3 cells, and sphere size and number
were assessed. The sphere size of PYK2 knockdown
cells was significantly larger than the control, how-
ever, their number was significantly lower compared
to the control (Fig. 6a, b and c). These differences
were more significant in response to metformin treat-
ment. Breast cancer stem cells are characterised by
the phenotype CD44High/CD24Low/− and ALDHHigh
Fig. 4 PYK2 expression and HER2+/ER−/PR- breast cancer patients’ survival. a, c, d Kaplan–Meier plots representing correlations between high or
low levels of PYK2 expression and percentage of survival of HER2+/ER−/PR- breast cancer patients (a) Total population of breast cancer patients c
and total populations of breast cancer patients excluding HER2+/ER−/PR- breast cancer patients d. b Cox regression analysis of correlation
between PYK2 expression and survival of HER2+/ER−/PR- breast cancer patients
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[37] and therefore, we investigated if our sphere
forming cells possess this phenotype, and if this
correlates with the results of sphere formation assays.
Indeed, our spheres were found to be enriched with
cells that had a CD44High/CD24Low/− and ALDHHigh
phenotype (Fig. 6d and e) Moreover, knockdown of
PYK2 resulted in a decrease of the percentage of
CD44High/CD24Low/− and ALDHHigh cells, while met-
formin treatment promoted the enrichment of these
cells (Fig. 6d and e). We also investigated the invasive
capacity of untreated and metformin-treated control
and PYK2 knockdown SkBr3 spheres and we found
that PYK2 knockdown significantly reduced their in-
vasive potential (Fig. 6f ). The results above from
initiation, self-renewal and invasion also indicate that
the effect of metformin is PYK2-dependent. Finally,
multivariate cox regression analysis demonstrates a
significant reduction in cancer-specific survival over a
5-year term and that was associated with
co-expression of PYK2 and the stem cell marker
CD44 (Fig. 6g). This reduction was not affected by
metformin treatment. Taken together, these results in-
dicate that metformin promotes invasion mediated by
HER2+/ER−/PR- breast cancer stem cells.
Discussion
Although significant progress has been made in develop-
ing novel chemical compounds for cancer therapy, drug
resistance is becoming a serious therapeutic challenge
that hinders the efficiency of chemotherapies [1, 2]. As a
result, drug resistance is responsible for cases of relapse
and recurrence that lead to decreased survival in treated
cancer patients. Thus, a better understanding of the
mechanisms of chemoresistance will significantly con-
tribute to the design and selection of more efficient
compounds. Metformin is a small molecule drug that is
Fig. 5 Proteomic analysis of 3546 proteins showing several upregulated and downregulated proteins and related pathways in untreated controls
and metformin-treated and untreated PYK2 knockdown SkBr3 cells. a Heatmap representing the top 25 upregulated and downregulated proteins
in untreated control and PYK2 knockdown SkBr3 cells. b Heatmap representing the top 25 upregulated and downregulated proteins in untreated
control and PYK2 knockdown metformin-treated SkBr3 cells. N = 1 (6 replicates) (c, d) Schematic representation of identified downregulated and
upregulated proteins and related pathways that are in common and different between untreated and metformin-treated PYK2 knockdown cells.
e, f Schematic representation of identified downregulated and upregulated proteins and related pathways in untreated PYK2 knockdown cells.
g, h Schematic representation of identified downregulated and upregulated proteins and related pathways in metformin-treated PYK2
knockdown cells
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Fig. 6 (See legend on next page.)
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successfully used for the treatment of diabetes type 2
and that has been suggested as a new therapeutic drug
for several types of cancer. The choice of this drug for
cancer therapy is based on epidemiologic reports that in-
dicated that cancer patients affected with diabetes type 2
and treated with metformin, have reduced cancer risk
and improved clinical outcomes [38–41]. Metformin
exerts its anti-proliferative and pro-apoptotic functions
by inhibiting mitochondrial complex I and by activating
AMPK (5′ AMP-activated protein kinase). These actions
lead to (i) the increase in endogenous levels of reactive
oxygen species (ROS) and oxidative stress, resulting in
cell death of cancer cells; (ii) activation of AMPK that
inhibit mTOR pathway and activation of the tumour
suppressor p53 [42–47].
Breast cancer is a heterogenous disease that can be clas-
sified into different molecular subtypes based on clinico-
pathology assessment, testing for hormonal (ER/PR)
receptors and amplification of human epidermal growth
factor receptor 2 (HER2). Treatment of breast cancer var-
ies corresponding to the molecular subtype and involves
endocrine therapies that target the oestrogen-receptor
positive subtype, HER2 antibody-based targeting of
HER2-positive subtype; and chemotherapy for the triple
negative breast cancer [48–50]. Unfortunately, resistance
to these therapies is also observed in aggressive breast
cancer and needs for new chemotherapeutic compounds
are required. In this regard, metformin has been suggested
as potential drug for the treatment of breast cancer due to
reduced cancer incidence in metformin-treated patients,
and its anti-proliferative and pro-apoptotic effects on can-
cer cells.
In this study, we investigated the effect of metformin
on cancer cell lines reflecting different breast cancer
subtypes. Although, metformin effects were significantly
noticeable in all studied breast cancer cell lines, we
found that HER2+/ER−/PR- cancer cells were the most
resistant to metformin. Interestingly, this resistance was
associated with the activation of PYK2, a well-known
molecule involved in proliferation, survival, migration
and invasion. PYK2 has been involved in mediating
downstream signalling of Integrins, GrRH, CCKR,
inflammation-mediated by chemokine and cytokine
pathways, via ERK/MAP kinase, PI3K/STAT3, WNT/
b-catenin signalling pathways [26]. PYK2 expression has
also been shown to increase in early and advanced
ductal breast cancer, and this correlated with increased
expression of HER2 [28]. The increase of PYK2 expres-
sion following metformin treatment may be explained by
metformin activation of AMPK signalling that trigger
the ERK/MAP kinase pathway leading to PYK2 activa-
tion [51, 52]. These observations prompted us to investi-
gate further its role in HER2+/ER−/PR- cancer cell
proliferation and invasion, and in response to metfor-
min. We found that although metformin prevented pro-
liferation, it also induced a PYK2-mediated cell invasion
of HER2+/ER−/PR- cancer cells, and this was further
confirmed by proteomic analysis. For instance, several
proteins that are commonly downregulated in untreated
and treated PYK2 knockdown cells such as the Rho
GDP-dissociation inhibitor 2 GDIR2 (also known as
ARHGDIB) are involved in regulating cell adhesion,
migration and invasion. GDIR2 negatively regulates actin
reorganisation, that is mediated by Rho family members,
by regulating the GDP/GTP exchange reaction of Rho
proteins [53, 54]. Another example is the inositol-3-phos-
phate synthase INO1, that is found downregulated, plays a
role in p53-mediated growth suppression associated with
myo-inositol biosynthesis pathway [55, 56]. Commonly
upregulated proteins in untreated and treated PYK2
knockdown cells are associated with the upregulation of
several proteins involved in cellular metabolism that is
(See figure on previous page.)
Fig. 6 PYK2 and metformin promote the enrichment of HER2+/ER−/PR- CD44High/CD24Low/− and ALDHHigh breast cancer stem-like cells. a Images
of representative spheres from 10 days sphere formation assay using SkBr3 control and PYK2 knockdowns cells metformin treated and untreated.
Scale bar = 100 μm. b Graph representing sphere size quantification (μm) of spheres from SkBr3 control and PYK2 knockdowns cells metformin
treated and untreated. Student t-test, ****P = < 0.0001, ***P = 0.0009 (Empty vector vs. PYK2 shRNA1), ***P = 0.0003 (untreated PYK2 shRNA1 vs.
treated PYK2 shRNA1), ***P = 0.0002 (Treated PYK2 shRNA2vs. treated PYK2 shRNA2). N = 3 (3 replicates). c Graph representing average number of
spheres from SkBr3 control and PYK2 knockdowns cells metformin treated and untreated. Student t-test, **P = 0.0014 (untreated empty vector vs.
treated empty vector), *P = 0.0100 (untreated PYK2 shRNA1 vs. treated PYK2 shRNA1), *P = 0.0240 (untreated PYK2 shRNA2 vs. treated PYK2
shRNA2), **P = 0.0013 (Empty vector vs. PYK2 shRNA1), ***P = 0.0007 (Empty vector vs. PYK2 shRNA2). N = 3 (3 replicates). d Graph representing
percentage of CD44High/CD24Low cells quantified by flow cytometry from SkBr3 control and PYK2 knockdowns cells metformin treated and
untreated. Anova, *P = 0.0273 (Empty vector vs. PYK2 shRNA1), *P = 0.0182 (Empty vector vs. PYK2 shRNA2), **P = 0.0045 (Treated empty vector vs.
treated PYK2 shRNA1), *P = 0.0211 (Treated empty vector vs. treated PYK2 shRNA2), **P = 0.0059 (untreated empty vector vs. treated empty
vector), *P = 0.0208 (untreated PYK2 shRNA1vs. treated PYK2 shRNA1), **P = 0.0044 (untreated PYK2 shRNA2vs. treated PYK2 shRNA2). N = 3 (3
replicates). e Graph representing percentage of ALDHHigh cells quantified by flow cytometry from SkBr3 control and PYK2 knockdowns cells
metformin treated and untreated. Anova, *P = 0.0448 (Empty vector vs. PYK2 shRNA1), ***P = 0.0002 (Treated empty vector vs. treated PYK2
shRNA1), **P = 0.0033 (Treated empty vector vs. treated PYK2 shRNA1). N = 3 (3 replicates). f Cell invasion assay using SkBr3 control and PYK2
knockdowns cells metformin treated and untreated. and the corresponding data quantifying of number of invading cells (48 h with or without
treatment). Anova ****P = < 0.0001. N = 3 (2 replicates). g Multivariate cox regression analysis of PYK2 and CD44 expression and their association
with HER2+/ER−/PR- breast cancer patients’ survival over a 5-year term
Al-Juboori et al. Journal of Experimental & Clinical Cancer Research          (2019) 38:210 Page 12 of 14
essential tumour growth and progression. Further-
more, we also demonstrate that a high expression of
PYK2 is associated with a significant reduction in
cancer-specific survival of HER2+/ER−/PR- breast
cancer patients. PYK2 may also promote the emer-
gence of HER2+/ER−/PR- cancer stem-like cells that
may play a role in cancer chemoresistance, relapse
and recurrence in patients who may receive metfor-
min treatment in the future. This was further
confirmed by demonstrating a correlation between re-
duced survival in pure HER2 breast cancer patients
and expression of PYK2 and the stem cell marker
CD44. Although clinical trials are ongoing, testing
this possibility in the future using samples from
metformin-treated breast cancer patients and when
available, will certainly shed light on potential induc-
tion of cancer invasion by metformin in treated
patients.
Conclusions
Our data indicates that metformin promotes HER2+/ER
−/PR- breast cancer invasion through mechanisms
involving PYK2, and that future treatments should
consider potential complications resulting from
metformin-based therapies.
Additional files
Additional file 1: Figure S1. (A) Effect of metformin (25 mM) on
apoptosis of SkBr3, MDA-MB-453 and MDA-MB-468. Anova, ***P = 0.0001.
(B) (C) Immunoblot images representing PYK2 expression in SkBr3 and
MDA-MB-453 control (pLKO.1 empty vector) and PYK2 knockdown cells
following cell culture passages week 2, 5 and 8. (D) Immunoblot images
representing PYK2 expression in metformin treated and untreated MDA-
MB-468, MDA-MB-231, BT-474 and MCF7 cell lines. (JPG 1083 kb)
Additional file 2: Figure S2. The difference in invasion and migration
between metformin treated and untreated shRNA control and PYK-2
knockdown (KD) SkBr3 (A)(B) and MDA-MB-453 (C)(D) cells were calcu-
lated as ratios in comparison to the control of each cell line. Significance
of the effect is calculated using two-way ANOVA in GraphPad prism with
Tukey multiple comparison. Anova (SkBr3 proliferation), **P = 0.0059,
*P = 0.0173, **P = 0.0078, *P = 0.0109; Anova (SkBr3 invasion),
****P = < 0.0001; Anova (MDA-MB-453 proliferation) ***P = 0.0003,
****P = < 0.0001, ***P = 0.0006, ***P = 0.0002; Anova (MDA-MB-453
invasion) ****P = < 0.0001. (JPG 1251 kb)
Additional file 3: Figure S3. (A) Heatmap representing the top 25
upregulated and downregulated proteins in untreated control and PYK2
knockdown MDA-MB-453 cells. (B) Heatmap representing the top 25
upregulated and downregulated proteins in untreated control and PYK2
knockdown metformin-treated MDA-MB-453 cells. (JPG 1535 kb)
Additional file 4: Data S1. Statistical values for Fig. 1a, b, c and d.
(XLSX 41 kb)
Additional file 5: Data S2. Tables representing top 25 upregulated
proteins and top 25 downregulated proteins in SkBr3 untreated control
vs. untreated and treated PYK2 knockdown samples with Fc 2 ≥ − 2, and
confidence of 70%. (DOCX 26 kb)
Additional file 6: Data S3. Tables representing top 25 upregulated
proteins and top 25 downregulated proteins in MDA-MB-453 untreated
control vs. untreated and treated PYK2 knockdown samples with Fc 2 ≥
− 2, and confidence of 70%. (DOCX 15 kb)
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